{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:15Z","timestamp":1789404735660,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1111\/jth.15758","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T14:44:24Z","timestamp":1652366664000},"page":"1859-1867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM\/DFCI 2009 cohort"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0879-6261","authenticated-orcid":false,"given":"Emilie","family":"Chalayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15758_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA\u2010ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1111\/jth.15758_bb0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta\u2010analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15758_bb0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15758_bb0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta\u2010regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ"},{"key":"10.1111\/jth.15758_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2016.08.008","article-title":"Cost\u2010effectiveness analysis of low\u2010molecular\u2010weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma","volume":"145","author":"Chalayer","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15758_bb0035","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15758_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.critrevonc.2018.02.003","article-title":"Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature","volume":"124","author":"Annibali","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/jth.15758_bb0045","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open\u2010label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.15758_bb0050","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.15758_bb0055","article-title":"IMWG guidelines for the prevention of thalidomide\u2010 and lenalidomide\u2010associated thrombosis in myeloma","year":"2015","journal-title":"Int Myeloma Working Group"},{"key":"10.1111\/jth.15758_bb0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide\u2010 and lenalidomide\u2010associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1111\/jth.15758_bb0065","first-page":"553","article-title":"Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the myeloma XI study","volume":"130","author":"Bradbury","year":"2017","journal-title":"Blood. Am Soc Hematol"},{"key":"10.1111\/jth.15758_bb0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2016.05.003","article-title":"Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?","volume":"143","author":"Chalayer","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15758_bb0075","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15758_bb0080","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15758_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0272989X0102100106","article-title":"Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets","volume":"21","author":"Steyerberg","year":"2001","journal-title":"Med Decis Making"},{"key":"10.1111\/jth.15758_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide\u2010based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1111\/jth.15758_bb0095","first-page":"89","article-title":"Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: an observational cohort study","volume":"3","author":"Chalayer","year":"2019","journal-title":"RTPH"},{"key":"10.1111\/jth.15758_bb0100","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide\u2010based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta\u2010analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"10.1111\/jth.15758_bb0105","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.3390\/ijms22168955","article-title":"The proteasome inhibitor bortezomib induces apoptosis and activation in gel\u2010filtered human platelets","volume":"22","author":"Ghansah","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1111\/jth.15758_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.15758_bb0115","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s11239-021-02407-5","article-title":"Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE\u2010VTE score for venous thrombosis prediction in multiple myeloma","volume":"52","author":"Bravo\u2010Perez","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.15758_bb0120","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15758_bb0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug\u2013associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"10.1111\/jth.15758_bb0130","first-page":"S61","article-title":"IMPEDE VTE vs SAVED scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?","volume":"200","author":"Teste","year":"2021","journal-title":"Int Conf Thromb Hemost Issues Can"},{"key":"10.1111\/jth.15758_bb0135","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1002\/ajh.24454","article-title":"Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs","volume":"91","author":"Chalayer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15758_bb0140","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"NEJM"},{"key":"10.1111\/jth.15758_bb0145","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"key":"10.1111\/jth.15758_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s40064-016-1817-1","article-title":"Elevated D\u2010dimer and fibrinogen levels in serum of preoperative bone fracture patients","volume":"5","author":"Liu","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1111\/jth.15758_bb0155","first-page":"S13","article-title":"D\u2010dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma","volume":"213","author":"Charles","year":"2022","journal-title":"Int Conf Thromb Hemost Issues Can"},{"key":"10.1111\/jth.15758_bb0160","first-page":"29","article-title":"Abnormal metaphase cytogenetics adds to currently known risk\u2010factors for venous thromboembolism in multiple myeloma: derivation of the PRISM score","volume":"136","author":"Chakraborty","year":"2020","journal-title":"ASH"},{"key":"10.1111\/jth.15758_bb0165","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/jth.15758_bb0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-2003-44554","article-title":"Hyperviscosity syndrome in plasma cell dyscrasias","volume":"29","author":"Mehta","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15758_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13331","article-title":"Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma","volume":"104","author":"Hinterleitner","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.15758_bb0180","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2133.2008.08700.x","article-title":"Intravenous immunoglobulins induce CD32\u2010mediated platelet aggregation in vitro","volume":"159","author":"Pollreisz","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/jth.15758_bb0185","doi-asserted-by":"crossref","first-page":"H1195","DOI":"10.1152\/ajpheart.1994.266.3.H1195","article-title":"Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma","volume":"266","author":"Carr","year":"1994","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/jth.15758_bb0190","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"2020","author":"Rutjes","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.15758_bb0195","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma \u2013 choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15758_bb0200","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low\u2010molecular\u2010weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta\u2010analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15758_bb0205","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/10428194.2020.1713321","article-title":"Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies","volume":"61","author":"Sorigue","year":"2020","journal-title":"Leuk Lymphoma"}],"updated-by":[{"DOI":"10.1111\/jth.15838","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15758","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T06:09:55Z","timestamp":1690870195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622020724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1538783622020724"],"URL":"https:\/\/doi.org\/10.1111\/jth.15758","relation":{"erratum":[{"id-type":"doi","id":"10.1111\/jth.15838","asserted-by":"object"}]},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM\/DFCI 2009 cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}